open access
I-modulia® in clinical trials — the use of emollients in atopic dermatitis patients
open access
Abstract
Atopic dermatitis (AD) is a chronic, recurring and inflammatory skin disease. Clinically AD is characterised by severe pruritus and skin lesions of typical morphology and localisation dependent on patient’s age. Pathogenesis of AD is complex; genetic, immunological and environmental factors are strongly involved in the process. Recently impairment in function of epidermal barrier is believed to play an essential role in development of AD. Systematic use of emollients plays a key role in the process of restoring epidermal barrier and elimination of skin dryness and pruritus. I-modulia®, extract from bacteria Aquaphilus dolomiae (Neisseriaceae) is an innovative product used in new generation of emollients. It has unique anti-inflammatory and anti-pruritic properties. In the studies it was shown that I-modulia® significantly enhances synthesis of anti-inflammatory interleukin-10 and restores the normal function of regulatory T cells. These properties point out to its enability to suppress inflammation. According to guidelines the use of emollients is a mainstay therapy of AD as they play an active role in the therapeutic process via their anti-inflammatory and immunosuppresive action. Recent data show beneficial role of emollients in primary prophylaxis of AD and the clinicians strongly recommend their use from first days of child’s life.
Abstract
Atopic dermatitis (AD) is a chronic, recurring and inflammatory skin disease. Clinically AD is characterised by severe pruritus and skin lesions of typical morphology and localisation dependent on patient’s age. Pathogenesis of AD is complex; genetic, immunological and environmental factors are strongly involved in the process. Recently impairment in function of epidermal barrier is believed to play an essential role in development of AD. Systematic use of emollients plays a key role in the process of restoring epidermal barrier and elimination of skin dryness and pruritus. I-modulia®, extract from bacteria Aquaphilus dolomiae (Neisseriaceae) is an innovative product used in new generation of emollients. It has unique anti-inflammatory and anti-pruritic properties. In the studies it was shown that I-modulia® significantly enhances synthesis of anti-inflammatory interleukin-10 and restores the normal function of regulatory T cells. These properties point out to its enability to suppress inflammation. According to guidelines the use of emollients is a mainstay therapy of AD as they play an active role in the therapeutic process via their anti-inflammatory and immunosuppresive action. Recent data show beneficial role of emollients in primary prophylaxis of AD and the clinicians strongly recommend their use from first days of child’s life.
Keywords
atopic dermatitis; I-modulia®; emollients; treatment
About this articleTitle
I-modulia® in clinical trials — the use of emollients in atopic dermatitis patients
Journal
Issue
Article type
Review paper
Pages
139-143
Published online
2017-02-14
Page views
1594
Article views/downloads
4832
Bibliographic record
Forum Dermatologicum 2016;2(4):139-143.
Keywords
atopic dermatitis
I-modulia®
emollients
treatment
Authors
Joanna Narbutt
Aleksandra Lesiak
